Akeso Announces NMPA Acceptance of Second NDA for Gumokimab in Active Ankylosing Spondylitis
Announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for...

